Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB3 positive |
| Therapy | CDX-3379 |
| Indication/Tumor Type | head and neck squamous cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 positive | head and neck squamous cell carcinoma | predicted - sensitive | CDX-3379 | Phase I | Actionable | In a Phase I trial, CDX-3379 (KTN3379) treatment decreased tumor Erbb3 phosphorylation levels in 83% (10/12) of patients with head and neck squamous cell carcinoma, with 50% or more reduction in 58% (7/12) of patients, and 42% (5/12) patients achieved shrinkage of tumor burden (PMID: 31308059; NCT02473731). | 31308059 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (31308059) | Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. | Full reference... |